Qiagen N : “In pursuit of a life for every patient” – QIAGEN to host Global Solid Tumor Summit

• Two-day hybrid event (April 25 and 26) to address current challenges in cancer treatment and diagnostics
• Uniting researchers, oncologists and data specialists from all over the world to discuss recent developments in biomarker testing
• QIAGEN offers unmatched breadth of technologies from PCR and digital PCR (dPCR) to next-generation sequencing (NGS) for companion diagnostic development

Venlo, the Netherlands, April 18, 2023 - Under the theme "In pursuit of a life for every patient", QIAGEN will host the Global Solid Tumor Summit to address the current challenges in cancer treatment and diagnostics. The global burden of cancer remains significant. Cancers account for nearly 10 million annual deaths worldwide [1], making cancer the second leading cause of death worldwide. Solid tumors make up more than 90% of those cancers.

The Global Solid Tumor Summit, to be held on April 25 and 26 as a hybrid event, will focus on the importance of integrating biomarker testing into cancer care, with the aim of improving patient outcomes.

Numerous biomarkers contribute to the development of tumor growth. Identifying relevant mutations in critical genes allows to develop a targeted approach to cancer therapy, which has the potential to result in improved outcomes and survival rates. However, access to timely biomarker testing remains one of the most significant challenges in cancer treatment, with new biomarkers and technologies, changing clinical guidelines, and turnaround time for test results all contributing to the issue.

In a recent publication on access to personalized medicine in advanced non-small cell lung cancer (NSCLC) [2] , it was found that close to half of the patients were lost to precision oncology due to factors associated with getting biomarker test results.

As such, the Global Solid Tumor Summit aims to unite researchers, oncologists, data specialists, and cancer survivors to address these challenges and raise awareness on the important relevance of biomarker testing both in research and in clinical practice.

The event will feature presentations by renowned experts, including Professor Umberto Malapelle, Department of Public Health, University Federico II of Naples, Italy: "Only by sharing the experience among colleagues that work in different parts of the world, can you share a practical vision of the implementation of biomarker testing in both clinical practice and research settings. This provides us with the opportunity to recognize the best approaches, and in turn, the best possible clinical outcome for patients."

Addressing cancer is expensive, but the cost of not addressing it is even higher. A recent study [3] revealed that, without further investment into research, prevention and diagnostics, cancer is expected to cost the global economy an accumulated $25.2 trillion (international dollars) in healthcare costs and lost labor over the next 30 years.

"Cancer not only takes a toll on the physical and emotional wellbeing of patients but also imposes an enormous economic burden on individuals, families and society. However, advanced diagnostics and treatments can significantly reduce these costs by enabling early detection, personalized therapies, and better outcomes," said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN. "That's why we are excited to bring together global oncology experts to discuss the latest technological advances and the integration of biomarker testing into cancer care."

To join the Global Solid Tumor Summit on April 25 and 26 please register here.

QIAGEN: comprehensive solutions and innovative collaborations to advance cancer diagnostics and research

QIAGEN offers a comprehensive portfolio from sample collection to data interpretation that enables the detection and analysis of relevant biomarkers. The company is continuously striving to innovate and expand the range of biomarker testing workflows, further paving the path to precision medicine.

QIAGEN is also collaborating with more than 30 global pharmaceutical and biotechnology companies to develop and market companion diagnostics, which detect clinically relevant genetic abnormalities to provide insights that guide clinical decision-making in diseases such as cancer. QIAGEN has an unmatched depth and breadth of technologies from next-generation sequencing (NGS) to polymerase chain reaction (PCR) and digital PCR (dPCR) for companion diagnostic development. The menu further includes 11 PCR-based companion diagnostic assay for a broad range of indications that are FDA approved.

[1] American Cancer Society,https://www.cancer.org/about-us/our-global-health-work/global-cancer-burden.html
[2]Sadik H, et al. Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer. JCO Precis Oncol. 2022;6:e2200246.
[3] Chen, S. et al. JAMA Oncology,https://jamanetwork.com/journals/jamaoncology/fullarticle/2801798

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).